JSPR
Jasper Therapeutics, Inc.
Price Chart
Latest Quote
$0.52
+0.01 (+2.67%)
Current Price
| Previous Close | $0.51 |
| Open | $0.48 |
| Day High | $0.53 |
| Day Low | $0.46 |
| Volume | 1,324,168 |
Stock Information
| Shares Outstanding | 33.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.27M |
| EPS (TTM) | $-1.04 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Book/sh | $0.05 |
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 2.55% |
| Institutional Ownership | 39.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.74 |
| P/B | 10.38 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 36.40 |
| ATR | nan |
| Short Float | 19.24% |
| Short Ratio | 16.16 |
| Rel Volume | 3.31 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 1,324,168 |
| 2026-10-26 | $0.50 | 396,700 |
| 2026-10-23 | $0.51 | 323,500 |
| 2026-10-22 | $0.50 | 72,300 |
| 2026-10-21 | $0.50 | 358,800 |
| 2026-10-20 | $0.50 | 366,500 |
| 2026-10-19 | $0.48 | 391,500 |
| 2026-10-16 | $0.48 | 245,600 |
| 2026-10-15 | $0.53 | 380,000 |
| 2026-10-14 | $0.50 | 620,100 |
| 2026-10-13 | $0.50 | 429,300 |
| 2026-10-12 | $0.56 | 335,800 |
| 2026-10-09 | $0.57 | 261,900 |
| 2026-10-08 | $0.56 | 362,200 |
| 2026-10-07 | $0.57 | 365,200 |
| 2026-10-06 | $0.56 | 327,900 |
| 2026-10-05 | $0.59 | 376,000 |
| 2026-10-02 | $0.56 | 236,100 |
| 2026-10-01 | $0.60 | 294,600 |
| 2026-09-30 | $0.58 | 538,500 |
| 2026-09-29 | $0.62 | 915,700 |
| 2026-09-28 | $0.63 | 251,100 |
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on JSPR.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $83,883,000 | $76,239,000 | $68,861,000 | $51,196,000 |
| Other Income Expense | $6,341,000 | $-88,000 | $-803,000 | $12,810,000 |
| Other Non Operating Income Expenses | $-2,187,000 | $-88,000 | $-246,000 | $-115,000 |
| Net Non Operating Interest Income Expense | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Operating Expense | $83,883,000 | $76,239,000 | $68,861,000 | $51,196,000 |
| General And Administrative Expense | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Interest Income | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Interest Income | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Normalized Income | $-84,329,000 | $-71,269,000 | $-63,908,000 | $-50,610,000 |
| Net Income From Continuing And Discontinued Operation | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Total Operating Income As Reported | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Net Income Common Stockholders | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income Including Noncontrolling Interests | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income Continuous Operations | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Pretax Income | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Interest Income Non Operating | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Operating Income | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Special Income Charges | - | $0 | $18,000 | $5,725,000 |
| Per Share | ||||
| Diluted EPS | $-3.95 | $-4.89 | $-6.18 | $-10.30 |
| Basic EPS | $-3.95 | $-4.89 | $-6.18 | $-10.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-91,355,000 | $-74,866,000 | $-67,196,000 | $-63,146,000 |
| Total Unusual Items | $8,528,000 | $0 | $-557,000 | $12,925,000 |
| Total Unusual Items Excluding Goodwill | $8,528,000 | $0 | $-557,000 | $12,925,000 |
| Reconciled Depreciation | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| EBITDA (Bullshit earnings) | $-82,827,000 | $-74,866,000 | $-67,753,000 | $-50,221,000 |
| EBIT | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Diluted Average Shares | $19,168,110 | $14,584,870 | $10,439,034 | $3,648,276 |
| Basic Average Shares | $19,168,110 | $14,584,870 | $10,439,034 | $3,648,276 |
| Diluted NI Availto Com Stockholders | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Gain On Sale Of Security | $8,528,000 | - | $-575,000 | $7,200,000 |
| Research And Development | $63,104,000 | $55,821,000 | $51,785,000 | $34,627,000 |
| Selling General And Administration | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Other Gand A | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Restructuring And Mergern Acquisition | - | $0 | $-18,000 | $-5,725,000 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Total Assets | $35,779,000 | $79,899,000 | $94,892,000 | $48,361,000 |
| Total Non Current Assets | $1,134,000 | $4,088,000 | $5,954,000 | $6,630,000 |
| Other Non Current Assets | $530,000 | $1,237,000 | $1,760,000 | $1,176,000 |
| Current Assets | $34,645,000 | $75,811,000 | $88,938,000 | $41,731,000 |
| Other Current Assets | $664,000 | $646,000 | $295,000 | $364,000 |
| Prepaid Assets | $5,289,000 | $3,528,000 | $1,506,000 | $2,204,000 |
| Cash Cash Equivalents And Short Term Investments | $28,692,000 | $71,637,000 | $86,887,000 | $38,250,000 |
| Cash And Cash Equivalents | $28,692,000 | $71,637,000 | $86,887,000 | $38,250,000 |
| Receivables | - | $0 | $250,000 | $913,000 |
| Taxes Receivable | - | $0 | $250,000 | $250,000 |
| Other Receivables | - | - | - | $663,000 |
| Debt | ||||
| Total Debt | $1,235,000 | $1,813,000 | $2,786,000 | $3,651,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $724,000 | $1,814,000 | $2,786,000 |
| Current Debt And Capital Lease Obligation | $1,235,000 | $1,089,000 | $972,000 | $865,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $31,628,000 | $18,225,000 | $16,452,000 | $12,372,000 |
| Total Non Current Liabilities Net Minority Interest | $18,428,000 | $2,988,000 | $4,078,000 | $5,307,000 |
| Other Non Current Liabilities | $2,264,000 | $2,264,000 | $2,264,000 | $2,362,000 |
| Derivative Product Liabilities | $16,164,000 | $0 | $0 | $150,000 |
| Current Liabilities | $13,200,000 | $15,237,000 | $12,374,000 | $7,065,000 |
| Other Current Liabilities | $120,000 | $419,000 | $317,000 | $194,000 |
| Payables And Accrued Expenses | $10,256,000 | $10,629,000 | $9,318,000 | $4,419,000 |
| Payables | $6,220,000 | $4,027,000 | $4,149,000 | $1,768,000 |
| Accounts Payable | $6,220,000 | $4,027,000 | $4,149,000 | $1,768,000 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Total Equity Gross Minority Interest | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Stockholders Equity | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Retained Earnings | $-316,670,000 | $-240,869,000 | $-169,600,000 | $-105,135,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $27,996,819 | $15,022,122 | $11,163,896 | $3,804,567 |
| Share Issued | $27,996,819 | $15,022,122 | $11,163,896 | $3,804,567 |
| Tangible Book Value | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Invested Capital | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Working Capital | $21,445,000 | $60,574,000 | $76,564,000 | $34,666,000 |
| Capital Lease Obligations | $1,235,000 | $1,813,000 | $2,786,000 | $3,651,000 |
| Total Capitalization | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Additional Paid In Capital | $320,818,000 | $302,541,000 | $248,039,000 | $141,124,000 |
| Capital Stock | $3,000 | $2,000 | $1,000 | $0 |
| Common Stock | $3,000 | $2,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $724,000 | $1,814,000 | $2,786,000 |
| Current Capital Lease Obligation | $1,235,000 | $1,089,000 | $972,000 | $865,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,589,000 | $3,100,000 | $1,767,000 | $1,587,000 |
| Current Accrued Expenses | $4,036,000 | $6,602,000 | $5,169,000 | $2,651,000 |
| Net PPE | $604,000 | $2,851,000 | $4,194,000 | $5,454,000 |
| Accumulated Depreciation | $-4,814,000 | $-3,807,000 | $-2,460,000 | $-1,352,000 |
| Gross PPE | $5,418,000 | $6,658,000 | $6,654,000 | $6,806,000 |
| Leases | $2,711,000 | $2,711,000 | $2,477,000 | $2,477,000 |
| Other Properties | $2,015,000 | $3,025,000 | $3,440,000 | $3,592,000 |
| Machinery Furniture Equipment | $692,000 | $922,000 | $737,000 | $737,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Employee Benefits | - | - | $0 | $9,000 |
| Long Term Provisions | - | - | - | $18,000 |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-77,168,000 | $-63,154,000 | $-52,334,000 | $-46,434,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-77,161,000 | $-62,602,000 | $-52,067,000 | $-45,858,000 |
| Cash Flow From Continuing Operating Activities | $-77,161,000 | $-62,602,000 | $-52,067,000 | $-45,858,000 |
| Operating Gains Losses | - | $11,000 | $575,000 | $-7,200,000 |
| Investing Activities | ||||
| Capital Expenditure | $-7,000 | $-552,000 | $-267,000 | $-576,000 |
| Investing Cash Flow | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Cash Flow From Continuing Investing Activities | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Financing Cash Flow | $34,211,000 | $47,884,000 | $100,971,000 | $55,000 |
| Cash Flow From Continuing Financing Activities | $34,211,000 | $47,884,000 | $100,971,000 | $55,000 |
| Net Common Stock Issuance | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Common Stock Issuance | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Net Other Financing Charges | - | - | $-960,000 | - |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $29,109,000 | $72,054,000 | $87,304,000 | $38,667,000 |
| Beginning Cash Position | $72,054,000 | $87,304,000 | $38,667,000 | $85,046,000 |
| Changes In Cash | $-42,945,000 | $-15,250,000 | $48,637,000 | $-46,379,000 |
| Proceeds From Stock Option Exercised | $243,000 | $689,000 | $452,000 | $55,000 |
| Net PPE Purchase And Sale | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Sale Of PPE | $12,000 | $20,000 | $0 | - |
| Purchase Of PPE | $-7,000 | $-552,000 | $-267,000 | $-576,000 |
| Change In Working Capital | $-4,923,000 | $184,000 | $5,103,000 | $-649,000 |
| Change In Other Current Liabilities | $-1,670,000 | $-973,000 | $-945,000 | $1,131,000 |
| Change In Other Current Assets | $707,000 | $523,000 | $-584,000 | $-114,000 |
| Change In Payables And Accrued Expense | $-2,181,000 | $2,757,000 | $5,202,000 | $-1,315,000 |
| Change In Accrued Expense | $-4,374,000 | $2,879,000 | $2,821,000 | $836,000 |
| Change In Payable | $2,193,000 | $-122,000 | $2,381,000 | $-2,151,000 |
| Change In Account Payable | $2,193,000 | $-122,000 | $2,381,000 | $-2,151,000 |
| Change In Prepaid Assets | $-1,779,000 | $-2,123,000 | $767,000 | $312,000 |
| Other Non Cash Items | $-5,318,000 | $491,000 | $401,000 | $-5,390,000 |
| Stock Based Compensation | $6,713,000 | $6,619,000 | $5,211,000 | $4,091,000 |
| Asset Impairment Charge | $1,112,000 | $0 | - | - |
| Depreciation Amortization Depletion | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| Depreciation And Amortization | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| Net Income From Continuing Operations | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Change In Receivables | - | $0 | $663,000 | $-663,000 |
| Gain Loss On Sale Of PPE | - | $11,000 | $0 | - |
| Gain Loss On Investment Securities | - | - | $575,000 | $-7,200,000 |
Fetched: 2026-10-25